Misoprostol-is more research needed?

Mary Lou Moore
Author Information
  1. Mary Lou Moore: M ary L ou M oore is an associate professor in the Department of Obstetrics and Gynecology at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Abstract

Misoprostol (Cytotec) is a synthetic prostaglandin E1 analogue that was designed for the prevention and treatment of peptic ulcer associated with the use of nonsteroidal anti-inflammatory drugs. In obstetrics, misoprostol has been administered for induction of first and second trimester abortion, for induction of labor in the third trimester, and to control postpartum hemorrhage. None of these uses has been approved by the Food and Drug Administration. Nevertheless, misoprostol is widely used in the United States and throughout the world. Advantages are cited as reduced rate of cesareans, shorter time from induction to birth and, particularly in developing countries, lower cost, oral, vaginal or rectal administration, and stability without refrigeration. Disadvantages are uterine hyperstimulation and, in rare instances, uterine rupture and death. Mothers should be informed of both the risks and the possible benefits of misoprostol. Further research with large samples is necessary to determine whether the risks outweigh any possible benefits.

References

  1. Int J Gynaecol Obstet. 2002 Jan;76(1):77-8 [PMID: 11818098]
  2. N Engl J Med. 2001 Jan 4;344(1):38-47 [PMID: 11136959]
  3. Clin Obstet Gynecol. 2000 Sep;43(3):469-74 [PMID: 10949751]
  4. Cochrane Database Syst Rev. 2003;(1):CD000941 [PMID: 12535398]
  5. Obstet Gynecol. 2002 Feb;99(2):316-32 [PMID: 11814515]
  6. Med Sci Law. 2000 Jan;40(1):78-82 [PMID: 10689866]
  7. Gynecol Obstet Invest. 2000;50(3):212-3 [PMID: 11014958]
  8. Eur J Obstet Gynecol Reprod Biol. 2001 Dec 1;99(2):152-3 [PMID: 11788162]
  9. Am J Obstet Gynecol. 1999 Jun;180(6 Pt 1):1535-42 [PMID: 10368501]
  10. Int J Gynaecol Obstet. 2001 Apr;73(1):1-6 [PMID: 11336714]
  11. Obstet Gynecol. 2001 Apr;97(4):603-7 [PMID: 11275035]
  12. Obstet Gynecol. 1998 May;91(5 Pt 2):828-30 [PMID: 9572178]
  13. Natl Vital Stat Rep. 1999 Apr 29;47(18):1-96 [PMID: 10334087]
  14. Am J Obstet Gynecol. 1996 Jul;175(1):158-64 [PMID: 8694043]
  15. Int J Gynaecol Obstet. 2001 Dec;75(3):235-41 [PMID: 11728483]
  16. Int J Gynaecol Obstet. 2002 Jan;76(1):65-74 [PMID: 11818096]
  17. Am Fam Physician. 2000 Jul 15;62(2):445 [PMID: 10929705]

Word Cloud

Created with Highcharts 10.0.0misoprostolinductiontrimesteruterineriskspossiblebenefitsresearchMisoprostolCytotecsyntheticprostaglandinE1analoguedesignedpreventiontreatmentpepticulcerassociatedusenonsteroidalanti-inflammatorydrugsobstetricsadministeredfirstsecondabortionlaborthirdcontrolpostpartumhemorrhageNoneusesapprovedFoodDrugAdministrationNeverthelesswidelyusedUnitedStatesthroughoutworldAdvantagescitedreducedratecesareansshortertimebirthparticularlydevelopingcountrieslowercostoralvaginalrectaladministrationstabilitywithoutrefrigerationDisadvantageshyperstimulationrareinstancesrupturedeathMothersinformedlargesamplesnecessarydeterminewhetheroutweighMisoprostol-isneeded?

Similar Articles

Cited By